News

Using artificial intelligence to discover new treatments for superbugs

Machine learning is pointing researchers toward molecules that are structurally different from current antibiotics
Fabiola De Marchi
By Fabiola De Marchi
July 11, 2021

Antimicrobial resistance is an emerging threat to healthcare systems worldwide. As a consequence of the spread of drug-resistant bacteria, also called “superbugs,” medical treatments could become ineffective for an increasing number of people in the next years. To fix this huge problem, chemists are asked to find new effective antibiotics. 

Superbugs-445x297.jpg
Alexander Klepnev on Wikimedia Commons.

Drug discovery is an expensive and time-consuming process during which pharmaceutical chemists look for new candidate molecules to interact with a particular target protein or pathway causing the disease. Chemists screen large libraries of thousands to millions of molecules, looking for compounds with specific biological effects and low toxicity. However, these screenings are not very efficient: if chemical libraries don’t include molecules with enough structural diversity, chemists will fail to discover antibiotics with molecular structures different from the ones already tested in laboratories or clinical trials. 

Now machine learning is flanking chemoinformatics through innovative deep neural network approaches to find new drugs. An example of how this approach works can be seen in a recent study by James Collins and coworkers at MIT. First, researchers trained a neural network model to predict growth inhibition of Escherichia coli using a set of 2335 diverse molecules; then, they applied the optimized neural network model to screen large chemical libraries with more than 107 million molecules. 

Recent improvements in machine learning can speed up and lower the costs of drug discovery

They ended up with a list of candidate molecules structurally different from known antibiotics, and ranked them based on their predicted biological activity. Among those candidates, they found that halicin, a compound under investigation as a treatment for diabetes, displayed high efficacy against E. coli and a large spectrum of pathogens such as Acinetobacter baumanii, at the top list of resistant bacteria which urgently requires new antibiotics.

Research groups are currently developing similar deep learning approaches to find new compounds that could fight the COVID-19 virus. This suggests how recent improvements in machine learning can assist chemists’ work to speed up and lower the costs of the drug discovery process.

This story originally appeared on Massive Science, an editorial partner site that publishes science stories by scientists. Subscribe to their newsletter to get even more science sent straight to you.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Fabiola De Marchi
Fabiola De Marchi

Fabiola De Marchi is a science writer for Massive Science.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.